The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
Neil Howard Segal
Consultant or Advisory Role - MedImmune
Research Funding - MedImmune
Scott Joseph Antonia
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - MedImmune
Julie R. Brahmer
Research Funding - MedImmune
Other Remuneration - MedImmune
Michele Maio
Consultant or Advisory Role - MedImmune
Research Funding - MedImmune
Andy Blake-Haskins
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Xia Li
Employment or Leadership Position - MedImmune
Jim Vasselli
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Ramy A. Ibrahim
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Jose Lutzky
Research Funding - MedImmune
Samir Khleif
Research Funding - MedImmune